Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer's Disease Portfolio at CTAD 2026
Roche receives FDA 510 clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema , a Serious Cause of Vision Loss
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
Genentech and Breastcancer.org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
SAGA Metals Reports 8 Completed Drill Holes at Trapper North Aimed to Expand the MRE at the Radar Critical Minerals Project
Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District
Red Metal Reports Mine Sampling at Farellon, Including 6.8% Copper on Level 7 and 6.05% Copper on Level 9
